Aytu BioPharma, Inc.
AYTUHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Aytu BioPharma, Inc. (AYTU) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $20.6M market cap, placing it firmly in the micro-cap category. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Market Cap
$20.6M
Beta
0.18
P/E (TTM)
—
P/E (Fwd)
12.26
EPS (TTM)
$-1.12
EPS (Fwd)
$0.15
ROE
-52.5%
ROA
-4.5%
Cash
$26.3M
Total Debt
$18.1M
Free CF
$5.6M
52W Change
-16.3%
Annual Financials
Cash vs Debt
Where AYTU stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AYTU finished 14.41% below its 150-day moving average ($2.29) and 16.60% below its 200-day moving average ($2.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AYTU overbought or oversold?
At the October 20, 2026 close, AYTU's RSI(14) was 25.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aytu BioPharma, Inc. holds $26.3M in cash against $18.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $5.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -52.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $107.4M (2023) to $57.6M (2026), a 46% decline worth watching.
The relatively low beta of 0.18 suggests AYTU is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing AYTU's risk profile alongside its fundamentals and technical indicators provides a more complete picture.